Major depressive disorder rose during the COVID-19 pandemic in USA, with nearly 30% adults having more symptoms of depression making it necessary to take a note of the situation. Working in this direction, Houston-based, Pharmaceutical company Fabre-Kramer has recently got FDA approval for its new anti-depressant medicine Gepirone hydrochloride, branded as Exxua which will be launched early next year in 2024.
The USP of Exxua is that this new depression drug avoids the common side effects like weight gain and sexual dysfunction found with other drugs for depression. This drug is the first and only approved antidepressant with a novel mechanism of action that selectively targets the serotonin 1A receptor which is a key regulator of emotion and mood. Exxua in trials done on 5000 people showed mild and brief periods of dizziness and nausea as the most frequent side effects.
Exxua definitely represents an important milestone in the management and treatment of major depressive disorder which is a serious and debilitating condition affecting millions of people worldwide.